Skip to Main Content
  • Become an Access Reviewer
  • Clinical Phenotypes
  • OMMBID Advisory banner
  • Ommbid banner
  • Ommbid latest banner



  1. Somatically acquired chromosomal translocations activate proto-oncogenes in the hematopoietic cells of both children and adults. This mechanism of gene dysregulation contributes to well over 50 percent of all leukemias that have been characterized cytogenetically and molecularly and to a substantial proportion of lymphomas, notably the Burkitt, large-cell, and follicular types.

  2. In most instances, chromosomal translocations fuse sequences of a transcription factor or receptor tyrosine kinase gene to those of a normally unrelated gene, resulting in a chimeric protein with oncogenic properties. Repositioning of transcriptional control genes to the vicinity of highly active promoter/enhancer elements, such as those associated with immunoglobulin or T-cell receptor genes, is a second mechanism by which chromosomal translocations induce malignancy.

  3. The vast majority of translocation-induced leukemias and lymphomas are restricted to cells of a single lineage arrested at a particular stage of development, indicating that the disrupted genes regulate vital processes limited to a subset of committed hematopoietic progenitors. Occasionally, as exemplified by leukemias arising from MLL gene abnormalities, more than one lineage or developmental stage is affected, suggesting the involvement of genes active in pluripotent or bipotent stem cells.

  4. The number of fusion genes with diagnostic and prognostic relevance is increasing rapidly. The hybrid mRNAs produced by these novel structures provide specific molecular probes for identifying affected patients who cannot be diagnosed readily by conventional means or who require chemotherapy tailored to the risk conferred by a particular genetic lesion.

  5. Studies in murine models, in which specific genes are mutated and homozygously inactivated in “knockout” mice or overexpressed in transgenic mice, have contributed new insights into the essential roles that are played in normal development and oncogenesis by genes discovered because of their proximity to the breakpoints of chromosomal translocations in the human leukemias and lymphomas.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

OMMBID Full Site: One-Year Subscription

Connect to the full suite of OMMBID content including new and revised chapters that reflect the latest research, image galleries, clinical phenotypes, and more.

$295 USD
Buy Now

Pay Per View: Timed Access to all of OMMBID

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.